Avall Lundqvist E H, Sjövall K, Eneroth P H
Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden.
Eur J Cancer. 1991;27(10):1313-5. doi: 10.1016/0277-5379(91)90103-k.
The objective was to evaluate if variations in serum alkaline DNase activity (SADA) can predict the effects of therapy in women with early stages of primary cervical carcinoma. 29 out of 33 patients had no evidence of disease after therapy. Only 5 out of the 29 women showed increased SADA levels after therapy compared with the pretreatment SADA value. Of the 4 women with evidence of disease after therapy, 3 had unchanged or decreased SADA levels. We conclude that serum alkaline DNase activity seems to have little to offer in predicting the effects of treatment in stage I and stage II cervical carcinoma.
目的是评估血清碱性脱氧核糖核酸酶活性（SADA）的变化是否能预测原发性宫颈癌早期女性患者的治疗效果。33例患者中有29例在治疗后无疾病迹象。29名女性中只有5名在治疗后的SADA水平与治疗前的SADA值相比有所升高。在治疗后有疾病迹象的4名女性中，3名的SADA水平未变或下降。我们得出结论，血清碱性脱氧核糖核酸酶活性在预测I期和II期宫颈癌的治疗效果方面似乎作用不大。
